NMPA approvals

Quadrivalent HPV Vaccine

Aiweijia: China’s First Domestic Quadrivalent HPV Vaccine Completes Full Homegrown HPV Lineup

NMPA has approved China’s first domestic quadrivalent HPV vaccine (Aiweijia) from Sinopharm’s CNBG. Following the launch of domestic bivalent and nine-valent vaccines, and after Merck’s Gardasil, it is the second quadrivalent on the Chinese market, targeting HPV 6/11/16/18 for women aged 18–45.

dulaglutide biosimilar

China Approves Boyouping® (BA5101), the World’s First Dulaglutide Biosimilar and First Domestic Product

China’s NMPA approved Boyouping® (BA5101), the world’s first dulaglutide biosimilar and first domestic product for type 2 diabetes. Developed by Boan Biotech and commercialized by Shanghai Pharma, Boyouping® matches Eli Lilly’s Trulicity® in efficacy and safety, with plans for global expansion.